Outcome of very late relapse in children with acute lymphoblastic leukemia

Haematologica

Volumn 89, Issue 4, 2004, Pages 427-434

  Rizzari, Carmelo ^a,j   Valsecchi, Maria Grazia ⁱ   Arico, Maurizio ^f   Miniero, Roberto ^h   Messina, Chiara ^b   De Rossi, Giulio ^c   Testi, Anna Maria ^g   Mura, Rossella ^d   Galimberti, Stefania ⁱ   Biondi, Andrea ^a   Locatelli, Franco ^e   Conter, Valentino ^a  

^a Pediatric Department of Monza   (Italy)

^b Pediatric Department of Padua   (Italy)

^c BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^d Pediatric Department of Cagliari   (Italy)

^e Pediatric Department of Pavia   (Italy)

^f Ospedale dei Bambini G Di Cristina   (Italy)

^g Cattedra di Ematologia   (Italy)

^h Department of Medical Sciences ^*  (Italy)

ⁱ Section of Medical Statistics   (Italy)

^j SAN GERARDO HOSPITAL   (Italy)

more..

Author keywords

Acute lymphoblastic leukemia; Childhood; Relapse; Treatment

Indexed keywords

ASPARAGINASE; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; HYDROXYUREA; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TENIPOSIDE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BONE MARROW; CANCER CENTER; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; DOSE RESPONSE; FEMALE; FOLLOW UP; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; ORGAN DONOR; PROGNOSIS; TREATMENT OUTCOME;

ADOLESCENT; BONE MARROW; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; ITALY; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 2942709483     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Margolin JF, Steuber CP, Poplack DG. Acute Lymphoblastic Leukemia. In: Principles and Practice of Pediatric Oncology. Pizzo PA, Poplack DG, editors. Fourth edition. Lippincott, Williams Et Wilkins, Philadelphia; PA: USA. 2002. p. 489-544.
2. Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med 1998;339:605-13.
3. Gaynon PS, Qu RP, Chappell RJ, Willoughby ML, Tubergen DG, Steinherz PG, et al. Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse-the Children's Cancer Group experience. Cancer 1998;82:1387-95.
4. Rivera G, Hudson MM, Liu Q, Benaim E, Ribeiro RC, Crist WM, et al. Effectiveness of intensified rotational combination chemotherapy for late hematological relapse of childhood acute lymphoblastic leukemia. Blood 1996;88:831-7.
5. Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996;14:18-24.
6. Buhrer C, Hartmann R, Fengler R, Dopfer R, Gadner H, Gerein V, et al. Superior prognosis in combined compared to isolated marrow relapse in salvage therapy of childhood acute lymphoblastic leukemia. Med Pediatr Oncol 1993;21:470-7.
7. Henze G, Buchmann S, Fengler R, Hartmann R. The BFM relapse studies in childhood ALL: concepts of two multicenter trials and results after 2 1/2 years. Haematol Blood Transfus 1987;30:147-55.
8. Nygaard R, Moe PJ, Brincker H, Clausen N, Nyman R, Perkkio M, et al. Late relapse after treatment for acute lymphoblastic leukemia in childhood: a population-based study from the nordic countries. Med Pediatr Oncol 1989;17:45-7.
9. Jankovic M, Fraschini D, Amici A, Arico M, Arrighini A, Basso G, et al. Outcome after cessation of therapy in childhood acute lymphoblastic leukaemia. The Associazione Italiana Ematologia ed Oncologia Pediatrica (AIEOP). Eur J Cancer 1993;29A:1839-43.
10. Miniero R, Saracco P, Pastore G, Zurlo MG, Terracini B, Rosso P, et al. Relapse after first cessation of therapy in childhood acute lymphoblastic leukemia: a 10-year follow-up study. Italian Association of Pediatric Hematology-Oncology (AIEOP). Med Pediatr Oncol 1995;24:71-6.
11. Pui CH, Dodge RK, Look AT, George SL, Rivera GK, Abromowitch M, et al. Risk of adverse events in children completing treatment for acute lymphoblastic leukemia: St. Jude Total Therapy studies VIII, IX and X. J Clin Oncol 1991;9:1341-7.
12. Paolucci G, Masera G, Vecchi V, Marsoni S, Pession A, Zurlo MG. Treating childhood acute lymphoblastic leukaemia (ALL): summary of ten years' experience in Italy. ALL Steering Committee of the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). Med Pediatr Oncol 1989;17:83-91.
13. Vecchi V, Aricò M, Ceci A, Ceci A, Madon E, Mandelli F, et al. Risk-directed therapy for childhood acute lymphobiastic leukemia. Results of the Associazione Italiana Ematologia Oncologia Pediatrica '82 studies. Cancer 1993;72:2517-24.
14. Paolucci G, Vecchi V, Favre C, Miniero R, Madon E, Pession F, et al. Treatment of childhood acute lymphoblastic leukemia. Long-term results of the AIEOP-acute lymphoblastic leukemia 87 study. Haematologica 2001;86:478-84.
15. Conter V, Aricò M, Valsecchi MG, Rizzari C, Testi AM, Messina C, et al. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Munster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica. J Clin Oncol 1995;13:2497-502.
16. Rossi MR, Masera G, Zurlo MG, Amadori S, Mandelli F, Bagnulo S, et al. Randomized multicentric Italian study on two treatment regimens for marrow relapse in childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol 1986;3:1-9.
17. Marubini E, Valseechi MG. Analysing survival data from clinical trials and observational studies. J. Wiley Et Sons, Chichester, 1995. Ch. 3, 4, 6.
18. Vora A, Frost L, Goodeve A, Wilson G, Ireland RM, Lilleyman J, et al. Late relapsing childhood acute lymphoblastic leukemia. Blood 1998;92:2334-7.
19. Chessels JM, Leiper AD, Richards SM. A second course of treatment for childhood acute lymphoblastic leukemia: long term follow-up is needed to assess results. Br J Haematol 1994;86:48-54.
20. Chessels JM. Relapsed lymphoblastic leukemia in children: a continuing challenge. Br J Haematol 1998;102:423-38.
21. Borgmann A, Hartmann R, Schmidt H, Klingebiel T, Ebell W, Gobel U, et al. Isolated extramedullary relapse in children with acute lymphoblastic leukemia: a comparison of treatment results between chemotherapy and bone marrow transplantation. Bone Marrow Transplant 1995;15:515-21.
22. Uderzo C, Valsecchi MG, Bacigalupo A, Meloni G, Messina C, Polchi P, et al. Treatment of childhood acute lymphoblastic leukemia in second remission with allogeneic bone marrow transplantation and chemotherapy: ten-year experience of the Italian Bone Marrow Transplantation Group and the Italian Pediatric Hematology Oncology Association. J Clin Oncol 1995;13:352-8.
23. Barrett J, Horowitz MM, Pollock BH, Zhang MJ, Bortin MM, Buchanan GR, et al. Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. N Engl J Med 1994;331:1253-8.
24. Borgmann A, Schmid H, Hartmann R, Baumgarten E, Hermann K, Klingebiel T, et al. Autologous bone marrow transplants compared with chemotherapy for children with acute lymphoblastic leukemia in second remission: a matched-pair analysis. Lancet 1995;346:873-6.
25. Eckert C, Biondi A, Seeger K, Cazzaniga G, Hartmann R, Beyermann B, et al. Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet 2001 13;358:1239-41.